Zydus Lifesciences Limited has informed the Exchange about General Updates
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The USFDA conducted a surveillance inspection at Zydus Lifesciences' formulation manufacturing plant in Baddi, Himachal Pradesh, from August 4 to August 13, 2025. The inspection concluded with 4 observations, none of which were related to data integrity. The company stated it will work closely with the USFDA to address the observations expeditiously. This is a routine regulatory disclosure under SEBI LODR Regulation 30.
The 4 observations without data integrity issues are generally seen as manageable and not severe; near-term impact on stock is likely limited, though resolution timelines and any follow-up Form 483 classification will be monitored by investors.